Chilton Capital Management LLC lessened its holdings in AbbVie Inc (NYSE:ABBV) by 16.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,236 shares of the company’s stock after selling 1,011 shares during the quarter. Chilton Capital Management LLC’s holdings in AbbVie were worth $483,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Eagle Capital Management LLC boosted its position in shares of AbbVie by 2.3% during the third quarter. Eagle Capital Management LLC now owns 34,102 shares of the company’s stock worth $3,225,000 after purchasing an additional 769 shares in the last quarter. Stevens Capital Management LP boosted its position in shares of AbbVie by 7.7% during the third quarter. Stevens Capital Management LP now owns 370,702 shares of the company’s stock worth $35,061,000 after purchasing an additional 26,369 shares in the last quarter. Clarius Group LLC bought a new position in shares of AbbVie during the third quarter worth $277,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of AbbVie by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 115,506 shares of the company’s stock worth $10,920,000 after acquiring an additional 32,046 shares during the period. Finally, CLS Investments LLC raised its holdings in shares of AbbVie by 12.5% during the third quarter. CLS Investments LLC now owns 21,467 shares of the company’s stock worth $2,030,000 after acquiring an additional 2,378 shares during the period. 70.62% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:ABBV opened at $77.91 on Friday. AbbVie Inc has a 12 month low of $75.77 and a 12 month high of $107.25. The firm has a market cap of $115.04 billion, a P/E ratio of 9.85, a P/E/G ratio of 1.60 and a beta of 1.14.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.08. AbbVie had a net margin of 16.42% and a negative return on equity of 253.85%. The firm had revenue of $7.83 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the previous year, the business earned $1.87 EPS. The company’s revenue was down 1.3% compared to the same quarter last year. Analysts predict that AbbVie Inc will post 8.83 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $1.07 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $4.28 annualized dividend and a yield of 5.49%. AbbVie’s payout ratio is currently 54.11%.
In other AbbVie news, Vice Chairman Laura J. Schumacher sold 25,000 shares of AbbVie stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $80.00, for a total value of $2,000,000.00. Following the sale, the insider now directly owns 139,838 shares in the company, valued at approximately $11,187,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Azita Saleki-Gerhardt sold 15,797 shares of AbbVie stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $79.03, for a total transaction of $1,248,436.91. Following the completion of the sale, the executive vice president now owns 93,312 shares in the company, valued at $7,374,447.36. The disclosure for this sale can be found here. Insiders sold a total of 41,272 shares of company stock worth $3,286,290 over the last quarter. Company insiders own 0.08% of the company’s stock.
ABBV has been the topic of a number of research analyst reports. Argus lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Monday, March 25th. Barclays restated a “hold” rating and set a $86.00 price objective on shares of AbbVie in a report on Thursday, February 14th. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Credit Suisse Group upgraded shares of AbbVie to a “hold” rating and set a $79.00 price objective on the stock in a report on Thursday, January 17th. Finally, BMO Capital Markets upgraded shares of AbbVie from an “underperform” rating to a “market perform” rating and raised their price objective for the stock from $71.00 to $79.00 in a report on Sunday, April 28th. Six equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $94.95.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More: What is Forex?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).